KYMR VS AUPH Stock Comparison

Performance

KYMR
10/100

KYMR returned -38.95% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AUPH
100/100

AUPH returned -10.12% in the last 12 months. Based on SPY's performance of -21.06%, its performance is above average giving it a score of 100 of 100.

Sentiment

KYMR
69/100

KYMR had a bullish sentiment score of 68.98% across Twitter and StockTwits over the last 12 months. It had an average of 2.55 posts, 2.33 comments, and 0.61 likes per day.

AUPH
72/100

AUPH had a bullish sentiment score of 72.34% across Twitter and StockTwits over the last 12 months. It had an average of 264.82 posts, 283.21 comments, and 966.77 likes per day.

Technicals

KYMR
75/100

KYMR receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

AUPH
11/100

AUPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

KYMR
10/100

KYMR has missed earnings 11 times in the last 20 quarters.

AUPH
10/100

AUPH has missed earnings 10 times in the last 20 quarters.

Profit

KYMR
10/100

Out of the last 17 quarters, KYMR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AUPH
10/100

Out of the last 20 quarters, AUPH has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

KYMR
47/100

KYMR has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

AUPH
55/100

AUPH has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

Analyst Price Targets

KYMR

"Analyst Price Targets" not found for KYMR

AUPH
80/100

5 analysts offer 12-month price targets for AUPH. Together, they have an average target of 16.67, the most optimistic target put AUPH at 26 within 12-months and the most pessimistic has AUPH at 11.

All score calculations are broken down here to help you make more informed investing decisions

Kymera Therapeutics, Inc. Common Stock Summary

Nasdaq / KYMR

Healthcare

Biotechnology

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Aurinia Pharmaceuticals Inc Summary

Nasdaq / AUPH

Healthcare

Biotechnology

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Power up your portfolio